Compare GHM & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHM | DSGN |
|---|---|---|
| Founded | 1936 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.4M | 853.8M |
| IPO Year | 1994 | 2021 |
| Metric | GHM | DSGN |
|---|---|---|
| Price | $66.07 | $10.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $125.60 | $21.71 |
| AVG Volume (30 Days) | 177.5K | ★ 479.8K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.90 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $245,293,000.00 | N/A |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $11.09 | N/A |
| P/E Ratio | $195.50 | ★ N/A |
| Revenue Growth | ★ 16.86 | N/A |
| 52 Week Low | $52.57 | $5.73 |
| 52 Week High | $125.82 | $17.25 |
| Indicator | GHM | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.60 | 35.88 |
| Support Level | N/A | $9.78 |
| Resistance Level | $90.54 | $11.18 |
| Average True Range (ATR) | 3.85 | 0.67 |
| MACD | -1.25 | 0.02 |
| Stochastic Oscillator | 11.73 | 25.33 |
Graham Corp designs and manufactures mission-critical fluid, power, heat transfer, vacuum, and mixing technologies for the Defense, Energy & Process, and Space industries. In Defense, its equipment is used in nuclear and non-nuclear propulsion, power, fluid transfer, thermal management, and mixing systems. In Energy & Process industries, it supplies equipment for vacuum, heat transfer, mixing, and fluid transfer applications used in oil refining, chemical facilities, fertilizers, ethylene, methanol, energetics, food & beverage, medical, and alternative energy applications such as hydrogen and geothermal processes. In the Space industry, its equipment is used in propulsion, power, thermal management, mixing, and life support systems. It operates in the United States and other countries.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.